Ensign Peak Advisors
RLMD icon

Ensign Peak Advisors’s Relmada Therapeutics RLMD Stock Holding History

Ensign Peak Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,530
Closed -$1.54M – 2137
2022
Q3 		$1.54M Buy
41,530
+41,170
+11,436% +$1.14M ﹤0.01% 878
2022
Q2 		$7K Hold
360
– – ﹤0.01% 2151
2022
Q1 		$10K Hold
360
– – ﹤0.01% 2189
2021
Q4 		$8K Buy
+360
New +$8.01K ﹤0.01% 2192
2021
Q1 		– Sell
-2,560
Closed -$82K – 1877
2020
Q4 		$82K Sell
2,560
-8,015
-76% -$275K ﹤0.01% 1790
2020
Q3 		$398K Buy
10,575
+4,165
+65% +$161K ﹤0.01% 1583
2020
Q2 		$287K Buy
+6,410
New +$271K ﹤0.01% 1543

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's RLMD Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 41,530 shares — an estimated $1.54M sold.

Ensign Peak Advisors first reported a position in RLMD in Q2 2020 and held it in 7 quarters. The position peaked at $1.54M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 41,530 Relmada Therapeutics shares in Q4 2022, an estimated $1.54M.
  • Ensign Peak Advisors first reported a position in Relmada Therapeutics in Q2 2020 and held it in 7 quarters.
  • Ensign Peak Advisors's Relmada Therapeutics position peaked at $1.54M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.